Neurocrine (NBIX) director Kevin Gorman finishes RSU vesting, holds 516,893 shares

Rhea-AI Filing Summary

Neurocrine Biosciences director Kevin Charles Gorman reported routine equity compensation activity. On January 31, 2026, 5,142 restricted stock units converted into the same number of Neurocrine common shares at $0 exercise price. To cover taxes on this vesting, 2,845 shares were withheld by the company at $136.06 per share, and no shares were sold on the market.

After these transactions, Gorman beneficially owned 516,893 common shares, held by the Gorman and Blais Family Trust, over which he has voting and investment power. The vesting completed an RSU grant originally awarded on January 31, 2022.

Insider Trade Summary

5,142 shares exercised/converted

Mixed 3 txns

Insider GORMAN KEVIN CHARLES

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	5,142	$0.00	--
Exercise	Common Stock	5,142	$0.00	--
Tax Withholding	Common Stock	2,845	$136.06	$387K

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 519,738 shares (Direct)

Footnotes (1)

1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. 516,893 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and vested as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GORMAN KEVIN CHARLES

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		M		5,142	A	$0	519,738	D
Common Stock	01/31/2026		F		2,845(1)	D	$136.06	516,893(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(3)	01/31/2026		M			5,142	(4)	(4)	Common Stock	5,142	$0	0	D

Explanation of Responses:

1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.

2. 516,893 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

3. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

4. This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and vested as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NBIX director Kevin Gorman report on January 31, 2026?

Kevin Gorman reported the vesting and settlement of 5,142 restricted stock units into 5,142 shares of Neurocrine Biosciences common stock at a $0 exercise price, along with share withholding for taxes related to this RSU vesting event.

Did Neurocrine Biosciences (NBIX) director Kevin Gorman sell any shares in this Form 4 filing?

No market sale occurred. 2,845 Neurocrine Biosciences shares were withheld by the company solely to satisfy tax withholding obligations tied to RSU vesting, as explicitly stated, and the filing clarifies that no shares were sold in the open market.

How many NBIX shares does Kevin Gorman beneficially own after the reported Form 4 transactions?

After the reported transactions, Kevin Gorman beneficially owns 516,893 shares of Neurocrine Biosciences common stock, held by the Gorman and Blais Family Trust, over which he has voting and investment power according to the footnote disclosure.

What is the nature of the RSUs reported by NBIX director Kevin Gorman?

Each restricted stock unit represents a contingent right to receive one share of Neurocrine common stock. The RSU grant reported here vested in four annual installments from January 31, 2023 through January 31, 2026, finishing with 5,142 shares vesting in 2026.

When was the RSU grant to NBIX director Kevin Gorman originally awarded and how did it vest?

The RSU grant was awarded on January 31, 2022. It vested in four tranches: 5,141 shares on each of January 31, 2023, 2024, and 2025, and 5,142 shares on January 31, 2026, subject to the award’s terms and conditions.

How were tax obligations handled for Kevin Gorman’s RSU vesting in NBIX shares?

To satisfy tax withholding obligations from the RSU vesting, Neurocrine Biosciences withheld 2,845 shares from the vested amount at a price of $136.06 per share, and the disclosure notes that no shares were sold in the market as part of this withholding.